Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
CoronaVac is safe and well tolerated in older adults. Neutralising antibody titresinduced by the 3 μg dose were similar to those of the 6 μg dose, and higher than…
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2021 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
Continue Reading
-
Business18 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business20 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
General9 hours agoVictorian school teacher charged with soliciting child abuse material
-
General17 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips